ASTRAZEN - Swing Trade Analysis with AI Signals

Last Updated Time : 05 Nov 25, 7:43 am

✅ Swing Trade Rating: 3.8

Entry Zone: ₹9,450–₹9,580 (only if RSI < 65 and MACD sustains)

Exit if held: ₹10,600–₹10,690 (near 52W high and breakout zone)

📊 Technical & Fundamental Snapshot

• 📈 Current Price: ₹9,589
• 📈 52W High/Low: ₹10,691 / ₹6,220
• 📈 RSI: 62.8 (bullish, nearing overbought)
• 📈 MACD: 142 (strong bullish crossover)
• 📈 Volume: 18.7K vs 1W Avg 17.8K (steady)
• 📉 FII Holding Change: -0.29%
• 📈 DII Holding Change: +0.71%
• 📉 P/E: 113 vs Industry 33.1 (valuation premium)
• 📉 PEG Ratio: 2.62 — growth priced high

✅ Positive

• 📈 ROCE & ROE: 33.4% and 23.6% — strong capital efficiency.
• 📈 EPS: ₹73.3 — robust earnings base.
• 📈 MACD Bullish: Indicates strong momentum.
• 📈 Above DMA 50 & 200: Trend confirmation zone.
• 📈 Debt to Equity: 0.05 — minimal leverage.

⚠️ Limitation

• 📉 Valuation Stretch: P/E and PEG indicate premium pricing.
• 📉 FII Exit: Foreign investors trimmed exposure.
• 📉 Dividend Yield: 0.33% — low passive income.

🚨 Company Negative News

• 📉 Q2FY26 PAT: ₹56.1 Cr vs ₹62.3 Cr QoQ — slight sequential decline.
• 📉 Trading Window Closed: Ahead of Nov 7 board meeting, insider trading window remains shut.

📈 Company Positive News

• 🚀 Qtr Profit Var: +60.1% YoY — strong annual growth.
• 📈 Board Meeting: Scheduled for Nov 7 to review H1FY26 results — potential catalyst.
• 📈 Technical Strength: Stock has rallied 54% from 52W low, outperforming sector peers.

💊 Industry

• 📈 Deal Momentum: Pharma & healthcare deals surged 166% QoQ to $3.5B in Q3 2025.
• 📈 R&D Focus: MNC pharma firms investing in India for clinical trials and specialty therapies.

🧾 Conclusion

• ✅ Technically strong swing setup with MACD/RSI alignment and DII support.
• 📥 Entry near ₹9,450–₹9,580 if RSI < 65 and MACD sustains.
• 📤 Exit near ₹10,600–₹10,690 (resistance and 52W high zone).
• 📈 Momentum strong, valuation rich — suitable for alert-driven tactical trades with basket overlay.

Sources

Rediff – Board Meeting Intimation

Business Standard – Pharma Deal Surge

Economic Times – Stock Snapshot